ERBB2 and neoplasm: Thus, the anti-HER2 antibody conjugate 31 showed a strong in vivo efficacy against HER2-expressing breast, gastric, and lung murine tumor models at doses of 3–6 mg/kg, including tumors resistant to trastuzumab-DM1 [93].